ArticleBMC pediatrics2026
Oligoarticular juvenile idiopathic arthritis: epidemiological, clinical, therapeutic and outcome profile of a Tunisian cohort.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOligoarticular juvenile idiopathic arthritis (oJIA) is the most common subtype of juvenile idiopathic arthritis and is associated with a risk of chronic anterior uveitis and disease extension. Data from North Africa remain limited. This study aimed to describe the epidemiological, clinical, therapeutic, and outcome profile of Tunisian children with oJIA.
methodsWe conducted a retrospective longitudinal study of children diagnosed with oJIA and followed at a tertiary pediatric rheumatology center in Tunisia between January 1999 and December 2022. Demographic, clinical, ophthalmologic, laboratory, imaging, treatment, and outcome data were collected from medical records. Disease activity was assessed using the Juvenile Arthritis Disease Activity Score based on 10 joints (JADAS-10).
resultsEighty-two children were included, with a female predominance (67.1%). The mean age at disease onset was 4.4 years and the mean diagnostic delay was 9 months. Antinuclear antibodies were positive in 71% of patients, whereas rheumatoid factor was negative in all tested cases. Uveitis occurred in 20 patients (24.4%) and was asymptomatic in most cases; 85% of affected patients were ANA-positive. Ocular complications developed in 13 of the 20 patients with uveitis, most commonly posterior synechiae and cataract. Disease extension occurred in 18 patients (22%) and was confined to the first two years after disease onset. Methotrexate was prescribed in 52 patients (63.4%), while biologic therapy was indicated in 11 patients and administered to 8 (etanercept, n = 6; adalimumab, n = 2). After a mean follow-up of 5.8 years, disease activity progressively improved, with 88.3% of patients achieving inactive disease at 24 months. Articular complications were uncommon, and acceptable visual acuity was preserved in 14 of the 20 patients with uveitis.
conclusionsIn this single-center North African cohort, oJIA was characterized by early onset, frequent ANA positivity, and a substantial burden of chronic anterior uveitis. Disease extension occurred in approximately one-fifth of patients and was limited to the first two years of disease. Most patients achieved inactive disease despite restricted access to biologic therapies. These findings provide additional data on oJIA from North Africa and highlight the importance of systematic ophthalmologic screening and long-term monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.